Niemann-Pick Disease

Overview

“Niemann-Pick disease” is an umbrella term for rare inherited lysosomal storage disorders—conditions in which materials build up inside cells’ recycling compartments. Acid sphingomyelinase deficiency (ASMD), historically called Niemann-Pick types A, A/B, and B, results from variants in SMPD1 and can cause severe infantile brain disease or chronic lung, liver, spleen, blood, and lipid problems. Niemann-Pick type C (NPC) is a separate disorder caused by variants in NPC1 or NPC2, which disrupt intracellular cholesterol transport and can lead to liver disease in infancy and progressive problems with movement, swallowing, speech, thinking, and psychiatric symptoms later in life. Prognosis is highly variable: severe infantile forms can be fatal early, while childhood-onset NPC commonly progresses into early adulthood. ASMD GeneReviews NPC GeneReviews

There is not yet a cure for either ASMD or NPC. Current care combines multidisciplinary symptom management with disease-modifying medicines where available. In the United States, intravenous olipudase alfa is approved for non-central-nervous-system manifestations of ASMD, while NPC now has FDA-approved neurological treatments: arimoclomol with miglustat for people aged two years and older, and levacetylleucine for people weighing at least 15 kg. These treatments can slow or improve selected aspects of disease but do not repair the inherited genetic defect or reverse established brain injury. ASMD GeneReviews FDA: Miplyffa approval FDA: Aqneursa approval

Scope of Recent Research (2020–present)

Research since 2020 has been active across enzyme replacement for ASMD; medicines that improve lipid handling, protein quality control, or neurological function in NPC; and preclinical gene-replacement approaches intended to correct the underlying cause. The field has made meaningful progress toward disease modification—especially with three U.S. approvals across ASMD and NPC—but remains substantially short of a curative therapy, particularly because durable treatment must reach the brain as well as peripheral organs. ASMD GeneReviews NPC GeneReviews

Major Breakthroughs and Emerging Therapies

For ASMD, the major advance has been enzyme replacement therapy (ERT) with olipudase alfa, a recombinant version of the missing acid sphingomyelinase enzyme. In the randomized ASCEND phase 2/3 trial in adults, treatment improved lung gas transfer and reduced enlarged spleen and liver volumes over 52 weeks compared with placebo. This is an important proof that replacing the missing enzyme can modify systemic disease, but the enzyme does not cross the blood-brain barrier and therefore is not expected to treat the neurodegeneration of severe type A or A/B ASMD. ASCEND olipudase alfa trial ASMD GeneReviews

In NPC, cyclodextrins remain a leading cholesterol-mobilizing strategy. Hydroxypropyl-beta-cyclodextrin (HPβCD) is designed to help remove cholesterol trapped within cells. A 2022 phase 1 study of intravenous Trappsol Cyclo found changes consistent with biological activity in peripheral tissues and the central nervous system, including reduced cholesterol storage in liver tissue; however, hearing-loss stopping rules led two participants to withdraw. The central challenge is to maintain sufficient cholesterol clearance in vulnerable brain cells without causing dose-limiting ear toxicity. Intravenous Trappsol Cyclo phase 1 trial

Small-molecule therapies have also changed the NPC treatment landscape. Arimoclomol amplifies the heat-shock response, a cellular protein-maintenance system thought to improve lysosomal function. In its 50-participant phase 2/3 trial, arimoclomol slowed clinical progression over 12 months relative to placebo, with the strongest prespecified subgroup result among participants receiving background miglustat; the FDA approved arimoclomol as Miplyffa in combination with miglustat on September 20, 2024. Arimoclomol phase 2/3 trial FDA: Miplyffa approval

Levacetylleucine, also called N-acetyl-L-leucine, is a neurological treatment rather than a genetic correction. In a 60-participant randomized crossover trial, it improved a functional ataxia measure over 12 weeks compared with placebo, supporting its FDA approval as Aqneursa on September 24, 2024. These approvals are significant for daily function, but neither agent has demonstrated restoration of normal cellular lipid transport or a permanent halt to disease progression. N-acetyl-L-leucine trial FDA: Aqneursa approval

Nizubaglustat is an emerging oral, brain-penetrant candidate for NPC. It is intended to act on glycosphingolipid metabolism through a dual mechanism, reducing the production and enhancing the breakdown of selected stored lipids. In the small phase 2 RAINBOW study, six participants with NPC contributed to findings of dose-dependent reductions in plasma glucosylceramides; those biomarker results are encouraging but are not evidence of a cure or definitive clinical efficacy. RAINBOW nizubaglustat phase 2 study

Gene replacement remains the most directly curative concept because it seeks to provide functional NPC1, NPC2, or SMPD1 activity. It is still preclinical for Niemann-Pick disease. In a 2025 mouse study of NPC2 disease, an engineered AAV-BR1 viral vector delivering NPC2 engaged brain endothelial and neuronal cells, reduced lipid deposition, and improved neurological signs. Parallel work is optimizing compact NPC1 gene-control sequences for adeno-associated virus (AAV) delivery in mouse models. AAV-BR1 NPC2 gene therapy NPC1 AAV promoter study

Clinical Trials and Experimental Approaches

The completed ASCEND trial, sponsored by Genzyme/Sanofi, was a phase 2/3 randomized placebo-controlled study in 36 adults with ASMD. At week 52, olipudase alfa increased predicted lung diffusing capacity by 22% versus 3.0% with placebo and reduced spleen volume by 39% versus a 0.5% increase with placebo; the trial subsequently supported U.S. approval of Xenpozyme in 2022. Pediatric olipudase alfa studies have likewise reported improvements in non-neurological disease measures, but this ERT does not address central nervous system disease. ASCEND olipudase alfa trial FDA 2022 novel drug approvals Pediatric olipudase alfa study

For NPC, two prominent phase 3 programs are testing therapies that aim to slow neurological decline rather than cure the disease. Cyclo Therapeutics’ TransportNPC study is evaluating intravenous Trappsol Cyclo plus standard care against placebo plus standard care over 96 weeks in children and adults with NPC1. Azafaros’ NAVIGATE study is recruiting for an 18-month randomized, placebo-controlled phase 3 trial of oral nizubaglustat in late-infantile and juvenile NPC; it began on June 30, 2025, plans to enroll 72 participants, and has an estimated completion date of November 4, 2027. Earlier VTS-270 pediatric study plans were withdrawn before enrolling participants because of a business decision, illustrating the fragility of rare-disease development programs. TransportNPC trial record NAVIGATE nizubaglustat trial record Withdrawn VTS-270 pediatric study

Methodologies and Scientific Approaches

Researchers combine genetically engineered mouse models, patient-derived cells, and clinical natural-history data to test whether a treatment corrects lipid storage and meaningfully changes neurological decline. Human induced pluripotent stem cells—adult patient cells reprogrammed into stem cells and then differentiated into neurons or other affected cell types—are especially useful for testing therapies in human disease-relevant cells when direct access to brain tissue is impossible. iPSC models for NPC1 AAV-BR1 NPC2 gene therapy

Biomarker development is equally important. Liquid chromatography–mass spectrometry assays measure NPC-related molecules in blood or urine, including oxysterols, bile-acid derivatives, and N-palmitoyl-O-phosphocholineserine, previously called lyso-sphingomyelin-509. These measures can accelerate diagnosis and indicate peripheral biochemical response, but they do not reliably show whether a drug is preventing neurodegeneration in the brain; trials therefore pair biomarkers with clinical scales of walking, speech, swallowing, fine-motor control, and ataxia. NPC biomarker discovery Mass-spectrometry biomarkers for NPC

Leading Institutions and Funding

The field is driven by international clinical networks involving institutions such as the University of California San Francisco, Mayo Clinic, Great Ormond Street Hospital/UCL, University Hospital Bern, and the NIH, together with companies including Sanofi, Zevra Therapeutics, Cyclo Therapeutics, and Azafaros. Their roles range from running pivotal trials and maintaining natural-history cohorts to designing vectors that can reach the nervous system. Arimoclomol phase 2/3 trial ASCEND olipudase alfa trial NAVIGATE nizubaglustat trial record

Patient-led funding remains unusually important. The Ara Parseghian Medical Research Fund at the University of Notre Dame reports supporting 17 projects in its 2025–26 program and offers research grants of up to $125,000 for one year in its 2026 call. It also awarded the International Niemann-Pick Disease Registry a two-year, $200,000 grant to strengthen patient-led registry infrastructure and support newborn-screening work. Ara Parseghian Medical Research Fund grants Current APMRF funding INPDR registry grant announcement

Strengths, Limitations, and Challenges

A central strength is that the field now has validated ways to modify disease manifestations: ERT can substantially improve ASMD lung and organ disease, while FDA-approved NPC medicines can improve or slow selected neurological outcomes. Better blood-based diagnostics, patient registries, and clinically meaningful neurological scales are also making rare-disease trials more feasible than they were at the beginning of the decade. ASCEND olipudase alfa trial NPC biomarker discovery FDA: Miplyffa approval

The core limitations are biological and practical. For severe ASMD and NPC, the brain is difficult to reach safely, and damage may be irreversible by the time treatment begins. HPβCD demonstrates why efficacy and safety must be solved together: its phase 1 intravenous study showed biological activity but also withdrawals linked to hearing loss. Cost and access can also constrain real-world benefit; for example, the United Kingdom’s NICE concluded in 2025 that olipudase alfa was not cost-effective for routine NHS use despite evidence of clinical improvement. Intravenous Trappsol Cyclo phase 1 trial NICE assessment of olipudase alfa

Outlook and Future Directions

As of August 8, 2026, Niemann-Pick research is closer to sustained disease modification than to a one-time cure. The most important near-term milestones are clinical results from TransportNPC and the phase 3 NAVIGATE nizubaglustat study, expected to complete in November 2027, alongside evidence that gene-delivery platforms can safely and durably correct disease in both the central nervous system and peripheral organs. A true cure will likely require early diagnosis, lifelong correction or long-lasting gene expression, broad tissue delivery, and proof that treatment prevents—not merely slows—neurological loss. TransportNPC trial record NAVIGATE nizubaglustat trial record AAV-BR1 NPC2 gene therapy

References

• ASMD GeneReviews — GeneReviews, 2023.
• NPC GeneReviews — GeneReviews, 2025.
• FDA: Miplyffa approval — U.S. Food and Drug Administration, 2024.
• FDA: Aqneursa approval — U.S. Food and Drug Administration, 2024.
• ASCEND olipudase alfa trial — Wasserstein et al., 2022.
• Pediatric olipudase alfa study — Diaz et al., 2021.
• FDA 2022 novel drug approvals — U.S. Food and Drug Administration, 2022.
• Intravenous Trappsol Cyclo phase 1 trial — Hastings et al., 2022.
• Arimoclomol phase 2/3 trial — Mengel et al., 2021.
• N-acetyl-L-leucine trial — Bremova-Ertl et al., 2024.
• RAINBOW nizubaglustat phase 2 study — López de Frutos et al., 2026.
• AAV-BR1 NPC2 gene therapy — Rasmussen et al., 2025.
• NPC1 AAV promoter study — Hsu et al., 2023.
• TransportNPC trial record — ClinicalTrials.gov, 2026.
• NAVIGATE nizubaglustat trial record — ClinicalTrials.gov, 2026.
• Withdrawn VTS-270 pediatric study — ClinicalTrials.gov, 2020.
• iPSC models for NPC1 — Ory et al., 2021.
• NPC biomarker discovery — Giese et al., 2022.
• Mass-spectrometry biomarkers for NPC — Maekawa and Mano, 2022.
• Ara Parseghian Medical Research Fund grants — University of Notre Dame, 2026.
• Current APMRF funding — University of Notre Dame, 2025.
• INPDR registry grant announcement — International Niemann-Pick Disease Registry, 2024.
• NICE assessment of olipudase alfa — National Institute for Health and Care Excellence, 2025.